Ozempic reduced grocery spending by an average of 5.3% in the US

Households with at least one GLP‑1 user cut grocery spend by ~5.3% within six months of adoption (larger declines — >8% — in higher‑income households), with sharp falls in spending on savory snacks (~10%), sweets and baked goods and an ~8% drop at fast‑food/limited‑service eateries; about one‑third of users discontinued during the 6‑month observation. For investors this signals modest demand headwinds for snack/processed‑food manufacturers and some QSR categories, potential re‑mixing toward fresh/yogurt/protein SKUs, and tailwinds for GLP‑1 drug makers and related pharma players — but uncertainty around durability (weight‑regain on cessation), payer coverage, regulatory limits and potential product reformulation keeps the market impact sector‑specific and limited in magnitude.

Analysis

Market structure: GLP‑1 adoption (household‑level ~5.3% grocery spend decline, ~16% early penetration) reweights demand away from ultra‑processed snacks toward fresh, dairy/protein and meal‑kits. Near‑term winners are large-format grocers and wholesalers with fresh perimeters and private‑label scale (WMT, KR, COST); losers are dollar/discount snack‑heavy formats (DG) and low‑margin packaged snack suppliers. Aggregate impact today is <1% national grocery revenue but is convex: if penetration rises to 25–30% or drug prices fall >30%, category‑level revenue shifts become material (Q3–Q4 2026).

Risk assessment: Tail risks include sudden insurer/PBM coverage cuts or regulatory limits on GLP‑1 prescribing (high‑impact, 30–180 day realization) which would reverse demand shifts and benefit snack incumbents; conversely rapid price declines or broader public funding would amplify effects. Hidden dependencies: producers can reformulate (high‑protein/“GLP‑1‑friendly”) and food makers will chase margins, muting retailer wins; commodity moves (sugar/corn/palm oil) are likely modest short term but could trend down 1–3% if adoption accelerates. Key catalysts: CMS/PBM policy announcements, new FDA approvals (reta/retatrutide), major PBM formulary coverage changes — monitor next 30–90 days.

Trade implications: Favor scalable grocers with private label and fresh logistics — overweight WMT/KR/COST through 3–12 months; underweight DG and niche QSRs with heavy snack exposure. Implement delta‑limited options: 3–6 month call spreads on KR/WMT to capture upside; 3‑month put spread on DG as asymmetric hedge. Rotate cash from packaged‑snack names into retailers and select foodservice names that pivot to higher‑margin protein/fresh offerings; expect EPS mix shifts by FY2026.

Key Decisions for Investors

• Establish a 2–3% long position split: 1.5% Kroger (KR) and 1.5% Walmart (WMT) via a mix of cash and 3–6 month call spreads (buy 1.5% notional 5%‑OTM call / sell 1.5% notional 15%‑OTM call). Rationale: capture mix shift to fresh/private label; target 12–18% IRR if same‑store fresh mix improves 150–300bps over 6–12 months.
• Initiate a 1–1.5% short or put‑spread position on Dollar General (DG) sized to risk tolerance (buy 3‑month 10%‑OTM put / sell 3‑month 25%‑OTM put). Thesis: DG is exposed to snack SKU weakness and lower basket margin; add to size if DG underperforms WMT by >15% within 90 days.
• Add a 1% long position in Costco (COST) via a 6‑month call spread (buy ATM call / sell 10%‑OTM call) to play bulk staple resilience and membership churn upside; trim if transaction metrics (avg spend/member) fall <‑2% YoY on next quarter print.
• Use a 1% notional 3‑month put spread on a broad QSR or restaurant ETF (or short a high‑exposure fast‑casual name) as a hedge against an 8–12% downside in limited‑service sales if GLP‑1 penetration expands >5 percentage points in 6 months. Execute within 30–60 days if CMS/PBM favorable rulings appear.
• Monitor (within 30–90 days) three binary catalysts before materially scaling positions: (A) PBM/formulary coverage change for tirzepatide/semaglutide; (B) branded GLP‑1 price move >‑30%; (C) Numerator/SSS data showing >10% drop in snack/fast‑food baskets among adopters. If two of three confirm, increase longs in WMT/KR/COST by additional 1–2% and add to DG hedge.